SCHEMBL888992

SCHEMBL888992

CC(C)(C)OC(=O)N1CCC[C@H]1CNc1nc2ccc(-c3ccc4nc(NC[C@@H]5CCCN5C(=O)OC(C)(C)C)sc4c3)cc2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
PIK3CG P48736 3/20 0.44
PIK3CA P42336 2/20 0.44
PI4KA P42356 2/20 0.44
PI4KB Q9UBF8 2/20 0.44
PRMT5 O14744 1/20 0.44
CHEK2 O96017 1/20 0.44
HCRTR1 O43613 2/20 0.43
DYRK2 Q92630 1/20 0.42
USP30 Q70CQ3 1/20 0.42
GPR119 Q8TDV5 2/20 0.42
PIK3CD O00329 2/20 0.42
PIK3CB P42338 1/20 0.42
ABL1 P00519 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HCRTR2 O43614 1/20 0.41
OPRD1 P41143 1/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12810003 0.91 L3MBTL1 (0.57) L3MBTL1PRMT5CHEK2USP30GPR119
SCHEMBL888984 0.88 L3MBTL1 (0.48) L3MBTL1PIK3CGPIK3CAPI4KAPI4KB
SCHEMBL12810166 0.88 L3MBTL1 (0.48) L3MBTL1PIK3CGPIK3CAPI4KAPI4KB
SCHEMBL13188727 0.81 L3MBTL1 (0.51) L3MBTL1ABL1NPC1RAB9AALDH1A1
SCHEMBL888972 0.79 CYP3A4 (0.47) PIK3CGPIK3CAPI4KAPI4KBHCRTR1
SCHEMBL12810189 0.75 FPR3 (0.45) L3MBTL1PRMT5USP30NPC1ALDH1A1
SCHEMBL18987182 0.75 USP30 (0.65) L3MBTL1PIK3CGPIK3CAPI4KAPI4KB
SCHEMBL888987 0.75 PRMT5 (0.48) PRMT5CHEK2HCRTR1USP30GPR119
SCHEMBL31286843 0.74 L3MBTL1 (0.48) L3MBTL1PIK3CGPIK3CAPI4KAPI4KB
SCHEMBL5097274 0.74 METTL3 (0.46) L3MBTL1PRMT5GPR119ALDH1A1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759332-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-06-24 US disclosed
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 L3MBTL1 2822/4885PIK3CG 601/4885PIK3CA 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.